Shares of PharmaCyte Biotech, Inc. (NASDAQ:PMCB – Get Free Report) traded down 0% during mid-day trading on Friday . The company traded as low as $1.60 and last traded at $1.64. 8,550 shares were traded during mid-day trading, a decline of 68% from the average session volume of 26,475 shares. The stock had previously closed at $1.64.
PharmaCyte Biotech Stock Performance
The business has a fifty day simple moving average of $1.70 and a 200 day simple moving average of $1.80. The stock has a market cap of $11.43 million, a price-to-earnings ratio of 2.48 and a beta of -0.21.
PharmaCyte Biotech (NASDAQ:PMCB – Get Free Report) last posted its quarterly earnings data on Friday, December 13th. The company reported ($0.29) EPS for the quarter.
About PharmaCyte Biotech
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
See Also
- Five stocks we like better than PharmaCyte Biotech
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Best Aerospace Stocks Investing
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- The 3 Best Retail Stocks to Shop for in August
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
